Recent advances in the categorization of childhood brain tumors have improved risk-based treatment planning. In several instances, new therapeutic strategies that incorporate these advances have resulted in meaningful improvements in progression-free and overall survival. Current studies are directed at further refining therapy based on clinical, biological, and molecular data; testing the effectiveness of a number of novel therapeutic strategies for high-risk tumors; and examining approaches to reduce sequelae of treatment among more favorable-risk tumor subsets. Because multiple tumor subtypes are individually relatively uncommon, most such studies are being conducted by large co-operative groups, such as the Children's Oncology Group, or by smaller brain tumor-focused consortia, such as the Pediatric Brain Tumor Consortium.
Pollack IFBrain tumors in children. N Engl J Med. 1994 ;331:1500-1507.
2.
Jennings MT, Sposto R., Boyett JM, et al. Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children's Cancer Group. J Clin Oncol. 2002;20:3431-3437.
3.
Radcliffe J. , Packer RJ, Atkins TE, et al. Three- and four-year cognitive outcome in children with noncortical brain tumors treated with whole-brain radiotherapy . Ann Neurol. 1992;32: 551-554.
4.
Evans AE, Jenkin RD, Sposto R., et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone . J Neurosurg.1990;72:572-582.
5.
Tait DM, Thornton-Jones H., Bloom HJG, Lemerle J., Morris-Jones P.Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I) . Eur J Cancer. 1990;26:464-469.
6.
Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol . 1999;17:832-845.
7.
Packer R., Gajjar A., Vezina G., et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy regimens for newly diagnosed average-risk medulloblastoma . J Clin Oncol. 2006;24:4202-4208.
8.
Pizer BL, Weston CL, Robinson KJ, et al. Analysis of patients with supratentorial primitive neuro-ectodermal tumours entered into the SIOP/UKCCSG PNET 3 study. Eur J Cancer . 2006;42:1120-1128.
9.
Thomas RM, Deutsch M., Kepner JL, et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol. 2000;18: 3004-3011.
10.
Gajjar A., Hernan R., Kocak M., et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol. 2004;22:984-993.
11.
Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD, Lunec J.Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res. 1997;57:3272-3280.
12.
Grotzter MA , Janss AJ, Fung K., et al. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol. 2000;18:1027-1035.
13.
MacDonald TJ , Brown KM, LaFleur B., et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease . Nat Genet. 2001;29:143-152.
14.
Pomeroy S., Goumnerova LC, Tamayo P., et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002;415:436-442.
15.
Northcott P. , Nakahara Y., Peacock J., et al. Identification of known and novel recurrent amplified oncogenes in pediatric medulloblastoma [abstract]. Neuro Oncol. 2007;9:554.
16.
Segal RA, Goumnerova LC, Kwon YK, Stiles CD, Pomeroy SLExpression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci U S A. 1994;91:12867-12871.
17.
Miralbell R. , Fitzgerald TJ, Laurie F., et al. Radiotherapy in pediatric medulloblastoma: quality assessment of Pediatric Oncology Group Trial 9031. Int J Radiat Oncol Biol Phys. 2006;64:1325-1330.
18.
Taylor RE, Bailey CC, Robinson KJ, et al. Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/ UKCCSG PNET-3 chemotherapy. Eur J Cancer . 2005;41: 727-734.
19.
Jakacki R., Burger P., Zhou T., et al. Outcome for metastatic (M+) medulloblastoma (MB) treated with carboplatin during craniospinal radiotherapy (CSRT) followed by cyclophosphamide (CPM) and vincristine (VCR). J Clin Oncol.2007;25:75S.
20.
Berman DM, Karhadkar SS, Hallahan AR, et al. Medulloblastoma growth inhibition by hedgehog pathway blockade . Science. 2002;297:1559-1561.
21.
Hallahan AR , Pritchard JI, Hansen S., et al. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res. 2004;64:7794-7800.
22.
Finlay JL, Boyett JM, Yates AJ, et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. J Clin Oncol. 1995;13:112-123.
23.
MacDonald TJ , Arenson EB, Ater J., et al. Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: final analysis of Children's Cancer Group Study 9933 . Cancer . 2005;104:2862-2871.
24.
Sposto R., Ertel IJ, Jenkin RD, et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group. J Neurooncol.1989;7:165-177.
25.
Wisoff JH, Boyett JM, Berger MS, et al. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945. J Neurosurg.1998;89:52-59.
26.
Pollack IF, Finkelstein SD, Woods J., et al. Expression of p53 and prognosis in malignant gliomas in children . N Engl J Med. 2002;346:420-427.
27.
Pollack IF, Hamilton RL, Burnham J., et al. The impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort. Neurosurgery . 2002;50: 1238-1244.
28.
Pollack IF, Hamilton RL, Sobol RW, et al. MGMT expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 cohort. J Clin Oncol. 2006;24: 3431-3437.
29.
Stupp R., Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med. 2005;352:987-996.
30.
Jakacki R., Yates A., Zhou T., et al. Temozolomide as part of combination chemotherapy for pediatric brain tumors: the Children's Oncology Group experience [abstract]. Neuro Oncol. 2007;9:188.
31.
Faury D., Nantel A., Dunn SE, et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol. 2007;25: 1196-1208.
32.
Khatua S., Peterson KM, Brown KM, et al. Overexpression of the EGFR/FKBP12/HIF-2alpha pathway identified in childhood astrocytomas by angiogenesis gene profiling. Cancer Res. 2003;63:1865-1870.
33.
Wong KK, Tsang YTM, Chang YM, et al. Genome-wide allelic imbalance analysis of pediatric gliomas by single nucleotide polymorphic allele array. Cancer Res . 2006;66:11172-11178.
34.
Fouladi M., Nicholson HS, Zhou T., et al. A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/ primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study. Cancer. 2007;110:2535-2541.
35.
Kieran MW, Packer RJ, Onar A., et al. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. J Clin Oncol. 2007;25:3137-3143.
36.
Pollack IF, Jakacki RI, Blaney SM, et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report . Neuro Oncol. 2007;9:145-160.
Dunkel IJ, Garvin JH, Goldman S., et al. High dose chemotherapy with autologous bone marrow rescue for children with diffuse pontine brain stem tumors. J Neurooncol . 1998;37: 67-73.
40.
Jenkin RD, Boesel C., Ertel I., et al. Brain-stem tumors in childhood: a prospective randomized trial of irradiation with and without adjuvant CCNU, VCR, and prednisone. A report of the Childrens Cancer Study Group. J Neurosurg.1987;66:227-233.
41.
Kretschmar CS, Tarbell NJ, Barnes PD, Krischer JP, Burger PC, Kun L.Pre-irradiation chemotherapy and hyperfractionated radiation therapy 66Gy for children with brain stem tumors. Cancer. 1993;72:1404-1413.
42.
Needle MN, Mehta M., Krailo M., et al. Phase I study of topotecan as a radiosensitizer prior to daily involved field irradiation in children with intrinsic pontine glioma. A Children's Cancer Group study [abstract]. Proc Am Soc Clin Oncol.1999;18:558a.
43.
Sanghavi SN , Needle MN, Krailo MD, et al. A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: first report of CCG-0952 . Neuro Oncol. 2003;1:8-13.
44.
Mehta M., Forouzannia A., Ames M., et al. Phase I study of motexafin-gadolinium (M-Gd) as a radiosensitizer for pediatric intrinsic pontine glioma (BSG): A Children's Oncology Group Study. Proc Am Soc Clin Oncol.2001;20:243a.
45.
Gilbertson RJ, Hill A., Hernan R., et al. ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin Cancer Res. 2003;9:3620-3624.
46.
Packer RJ, Ater J., Allen J., et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg. 1997;56:747-754.
47.
Prados MD, Edwards MS, Rabbitt J., Lamborn K., Davis RL, Levin VATreatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J Neurooncol. 1997;32:235-241.
48.
Ater J., Holmes E., Zhou T., et al. Treatment of young children with progressive or symptomatic low-grade glioma with chemotherapy: preliminary report from the Children's Oncology Group (COG) Phase 3 protocol A9952. Neuro Oncol. 2006;8:465.
49.
Bouffet E., Goldman S., Jakacki R., et al. Pilot study of vinblastine in patients with recurrent and refractory low grade glioma. Neuro Oncol. 2004;6:450.
50.
Wong KK, Chang YM, Tsang YTM, et al. Expression analysis of juvenile pilocytic astrocytomas by oligonucleotide micro-array reveals two potential subgroups. Cancer Res. 2005;65: 76-84.
51.
Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. New Engl J Med. 1993;328:1725-1731.
52.
Geyer JR, Sposto R., Jennings M., et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol. 2005;23:7621-7631.
53.
Rutkowski S. , Bode U., Deinlein F., et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. New Engl J Med. 2005;352:978-986.
54.
Biegel JA, Zhou J.-Y, Rorke LB, et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 1999;59:74-79.
55.
Judkins AR, Burger PC, Hamilton RL, et al. INI1 protein expression distinguishes atypical teratoid/rhabdoid tumor from choroid plexus carcinoma. J Neuropathol Exp Neurol . 2005;64:391-397.
56.
Hilden JM, Meerbaum S., Burger P., et al. Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. J Clin Oncol . 2004;22: 2877-2884.
57.
Tekautz TM, Fuller CE, Blaney S., et al. Atypical teratoid/ rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol. 2005;23:1491-1499.
